LG Chem is an established leader in pain management with a proven track record of delivering orthopedic pain solutions to ...

Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels ...

In its third quarter financial report, Pacira noted a 23 percent increase in Exparel net product sales, which hit $82.2 million for the quarter,. Due to recent positive coverage announcements from CMS ...

Pacira Pharmaceuticals reached an amicable resolution with the United States in a lawsuit filed earlier this year. The resolution confirms the company’s bupivacaine liposome injectable suspension ...

According to the American College of Surgeons, 15 million Americans undergo surgery each year. Despite this high frequency and the significant impact these procedures can have on patients, no ...

MIAMI (KFSN) -- Being told your child needs open heart surgery is frightening enough. A major concern is the pain after the procedure. Now a new type of anesthesia is proving to be a real game-changer ...

Pacira BioSciences PCRX reported preliminary, unaudited total revenues of $196.9 million for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of $199 million. The investors were ...

Please provide your email address to receive an email when new articles are posted on . Published results showed Exparel may be safe in patients aged 6 to younger than 17 years undergoing spine or ...

From the risks of opioid pain medications to alternative options, here’s how to advocate for a plan that helps your athlete ...

Pacira Pharmaceuticals announced results from a 200-patient study evaluating the benefits of Exparel (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain ...

Pacira Pharmaceuticals, Inc.PCRX announced that it has filed a lawsuit against the FDA seeking a court ruling to defend its rights to promote Exparel for the approved indication. Exparel, Pacira's ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...